Febrile neutropenia resident survival guide: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 94: Line 94:
</table></div>}}
</table></div>}}
{{familytree | | | | | | | |!| | | | | | |}}
{{familytree | | | | | | | |!| | | | | | |}}
{{familytree | | | | | | | F01 | | | | | |F01=<div style="float: left; text-align: center; width: 30em; padding:1em;">'''[[Febrile neutropenia# Multinational Association for Supportive Care in Cancer (MASCC) Risk Index|Do a risk assessment]]'''<br>'''(MANDATORY)'''<br>
{{familytree | | | | | | | F01 | | | | | |F01=<div style="float: left; text-align: left; width: 30em; padding:1em;">'''[[Febrile neutropenia# Multinational Association for Supportive Care in Cancer (MASCC) Risk Index|Do a risk assessment:]]''' '''(MANDATORY)'''<br>
<table class="wikitable">
<table class="wikitable">
<tr class="v-firstrow"><th>Variable</th><th>Weight</th></tr>
<tr class="v-firstrow"><th>Variable</th><th>Weight</th></tr>

Revision as of 18:38, 5 March 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Synonyms and keywords:

Definition

Neutropenic fever is defined as one oral temperature of ≥38.3°C (101°F) or a temperature of ≥38.0°C (100.4°F) for over one hour. Neutropenia is defined as an absolute neutrophil count (ANC) <500 cells/mm3 or an ANC that is expected to become less than 500 cells/mm3 over the next 48 hours. Profound neutropenia is defined as an ANC <100 cells/mm3. Patients with functional neutropenia have a qualitative abnormality of neutrophil functions despite a normal or elevated ANC, as seen in hematological malignancy, and are at increased risk of infections similarly to patients with low ANC.[1]

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Management

Initial Management

 
 
 
 
 
 
Characterize the symptoms:

Symptom suggestive of neutropenic fever:
❑ Fever in cancer patients who are on chemotherapy

❑ Single oral temperature ≥38.3° C (101° F)
or
❑ Temperature ≥38° C (100.4°F) sustained for over one hour

with
❑ Reduced absolute neutrophil count (ANC)

❑ ANC <500 cells/mm3
or
❑ ANC that is expected to decrease to <500 cells/mm3 in the next 48 hours
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider the diagnosis of neutropenic fever
POTENTIALLY LIFE THREATENING
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Obtain a detailed history:

❑ History of any symptom of infections and inflammation of

❑ Skin and soft-tissues
❑ Respiratory system
❑ Central nervous system
❑ Urinary tract

❑ History of any co-morbid conditions

❑ Diabetes mellitus
❑ Chronic obstructive lung disease

❑ History of any recent exposure to infections
❑ History of any current antibiotic prophylaxis
❑ History of non infectious causes of fever (example: administration of blood products)
❑ History of recent surgical procedures

❑ History of prior documentation of infections or pathogen colonization
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examine the patient:

❑ Search for signs of infections at

❑ Entry and exit sites of catheters in skin
❑ Sites of previous procedures in skin (example: bone marrow aspiration site)
❑ Oropharynx (including perioduntum)
❑ Lungs
❑ Alimentary tract
❑ Perineum
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order laboratory tests (routine):

CBC with

❑ Differential leukocyte count
❑ Platelet count

BMP
AST
ALT
Total bilirubin
❑ Blood cultures (at least 2 sets)

Central catheter1st set2nd set
❑ Present❑ From each lumen of existing central catheters❑ From a peripheral vein site
❑ Absent❑ From one separate venipuncture❑ From another separate venipuncture

❑ Urinalysis


Order additional tests (not routine and order if clinically indicated):

TestsClinical indications
❑ Urine culture❑ Urinary tract infection
❑ Urinary catheter in place
❑ Abnormal findings on urinalysis
❑ Chest X-ray❑ Respiratory tract infection
❑ CT head❑ CNS infection
❑ CT sinuses❑ Sinus infection
❑ CT abdomen❑ Infection of abdominal organs
❑ CT pelvis❑ Infection of pelvic organs
❑ Stool for clostridium difficile toxin assay❑ Diarrhea
❑ Stool for bacterial pathogen cultures or for ova and parasite❑ Diarrhea following a history of recent travel
❑ CSF analysis and culture❑ Meningitis
❑ Skin aspiration or biopsy for cytological testing, gram staining, and culture❑ Skin infection
❑ Sputum analysis❑ Productive cough
❑ Bronchoalveolar lavage and analysis❑ Infiltrations on chest imaging with an uncertain etiology
❑ Nasal wash or bronchoalveolar lavage and assays for viral detection❑ Respiratory infection during an outbreak or during winter
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Do a risk assessment: (MANDATORY)
VariableWeight
❑ No or mild symptoms in patients following an episode of febrile neutropenia❑ 5
❑ Absence of hypotension with a systolic blood pressure >90 mmHg❑ 5
❑ No chronic obstructive pulmonary disease (active chronic bronchitis, emphysema, decrease in forced expiratory volumes, need for oxygen therapy and/or steroids and/or bronchodilators)❑ 4
❑ Solid tumor or hematologic malignancy with no previously demonstrated fungal infection or empirically treated suspected fungal infection❑ 4
❑ Absence of dehydration that requires parenteral fluids❑ 3
❑ Moderate symptoms in patients following an episode of febrile neutropenia❑ 3
❑ Outpatient status❑ 3
❑ Age <60 years❑ 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low risk
❑ MASCC score ≥21
❑ Expected brief neutropenia (≤ 7 days)
❑ Clinically stable patient
❑ No comorbidities
 
 
 
High risk

❑ MASCC score <21, OR
❑ Expected prolonged neutropenia (> 7 days) AND profound neutropenia (ANC≤100 cells mm3), AND/OR

❑ Presence of comorbidities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outpatient oral antibiotics (Urgent)

❑ Ability to tolerate oral medications

❑ Availabilty of telephone, transportation to hospital, caregiver
 
Inpatient IV antibiotics (Urgent)

❑ Inability to tolerate oral medications
❑ Unavailabilty of telephone, transportation to hospital, caregiver

❑ Identified infection necessitating IV antibiotics
 
Inpatient IV antibiotics (Urgent)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Administer oral antibiotics:
ciprofloxacin + amoxicillin/clavulanate

Observe and discharge:

❑ Observe for 4 hours following the initial dose of antibiotics and discharge for outpatient treatment after making sure the patient is stable and tolerating the treatment
 
 
 
 
 
Administer IV monotherapy with an antipseudomonal:
Cefepime, OR
Piperacillin/tazobactam, OR
Carbapenem
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modify antibiotics if necessary:

Add vancomycin if:
❑ Suspected catheter related infection
❑ Suspected skin or soft tissue infection
❑ Suspected pneumonia
❑ Hemodynamic instability


Cover for organisms in case of previous infection, colonization, high endemicity:
MRSA: Add vancomycin, or linezolid or daptomycin
VRE: Add linezolid or daptomycin
ESBL: Add carbapenem
KPC: Add polymyxin, colistin or tigecycline

 
 

Management 2 to 4 Days After Initiation of Antibiotic Treatment

Do's

  • Modify the antibiotic regimens depending on the clinical picture and the epidemiology of infections in the area and the hospital where the patient is being treated at.

Don'ts

  • Don't measure the temperature of the patient in the axillary area because it is not as specific as if it was taken orally.
  • Don't measure the temperature of the patient rectally to avoid contaminating the skin and soft tissues of the rectal area.

References

  1. Freifeld, AG.; Bow, EJ.; Sepkowitz, KA.; Boeckh, MJ.; Ito, JI.; Mullen, CA.; Raad, II.; Rolston, KV.; Young, JA. (2011). "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america". Clin Infect Dis. 52 (4): e56–93. doi:10.1093/cid/cir073. PMID 21258094. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources